Protalix BioTherapeutics to Showcase Innovations at Nasdaq's BioConnect Conference
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a cutting-edge biopharmaceutical company known for its innovative approach to developing and commercializing recombinant therapeutic proteins, is set to make waves at the upcoming 3rd Annual H.C. Wainwright BioConnect Investor Conference. Scheduled for May 20, 2025, this conference will take place at the prestigious Nasdaq headquarters in New York City.
Key Presentation Details
Eyal Rubin, the Senior Vice President and Chief Financial Officer of Protalix, will represent the company at this significant investor event. He will deliver a presentation outlining the company's strategic direction and product pipeline, alongside being available for one-on-one meetings with investors throughout the conference.
Investors keen on interacting with Protalix’s management can reach out to representatives at H.C. Wainwright or can directly schedule their participation via email at ir@protalix.com.
Conference Information
- - Event: 3rd Annual H.C. Wainwright BioConnect Investor Conference
- - Date: Tuesday, May 20, 2025
- - Location: Nasdaq World Headquarters, 151 W. 43rd Street, New York City
A live webcast of the presentation will be accessible at 4:30 PM EDT, providing an opportunity for broader audiences to engage with Protalix's insights. Individuals can join the webcast via the following links:
About Protalix BioTherapeutics
Founded in Israel, Protalix BioTherapeutics is pioneering the development of recombinant therapeutic proteins through its unique ProCellEx® plant cell-based protein expression system. This innovative system allows Protalix to produce and commercialize therapies at a scale previously unattainable through traditional methods. Notably, Protalix was the first company to achieve FDA approval for a protein developed using plant cell suspension expression technology.
One of its significant partnerships includes licensing the worldwide rights for taliglucerase alfa, a treatment for Gaucher disease, to Pfizer, while maintaining rights in Brazil. Additionally, Protalix's product Elfabrio® received approvals from both the FDA and the European Medicines Agency in May 2023, bolstering its reputation in global markets.
The company continues to expand its pipeline with promising candidates like PRX–115, aimed at treating uncontrolled gout, and PRX–119, which targets NETs-related diseases. These enhancements reflect Protalix's commitment to addressing unmet medical needs through state-of-the-art biopharmaceutical innovations.
Investors and industry stakeholders interested in the advancements and future plans of Protalix BioTherapeutics are encouraged to engage during the BioConnect conference, a platform that merges innovative biotechnology with investment opportunities.
In summary, the 3rd Annual H.C. Wainwright BioConnect Investor Conference presents an excellent opportunity for Protalix to showcase its groundbreaking biopharmaceutical advancements, fostering relationships with investors and enhancing awareness of its pioneering therapies. As May 20 approaches, the anticipation surrounding Protalix's presentation continues to grow, reflecting the company's dedication to innovation and patient care.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.